Interleukin-8 in Hyperlipidemia and Coronary Heart Disease in Thai Patients Taking Statin Cholesterol-Lowering Medication While Undergoing Coronary Artery Bypass Grafting Treatment

Table 1

General description and clinical manifestations of the study population and the comparison between groups.

Variable	Normal	Hyperlipidemia	Coronary heart disease	value
	(N)	(H)	(CHD)
	(n = 13)	(n = 24)	(n = 18)	N vs. H	H vs. CHD	N vs. CHD
Age (year)	45.5 (23–59)	41 (26–58)	65.5 (58–78)	0.5577	<0.0001	<0.0001
TC (mg/dL)	178.5 (150–199)	226.5 (200–344)	171 (115–259)	<0.0001	0.0028	0.6548
TG (mg/dL)	164.5 (76–242)	172 (70–280)	84 (65–169)	0.9157	0.0183	0.0387
HDL (mg/dL)	42.5 (26–60)	45 (30–80)	49 (39–75)	0.5276	0.2624	0.1576
LDL (mg/dL)	113 (63–124)	145 (70–190)	90 (44–174)	0.0002	0.045	0.6932

All normal controls and patients were male. N = normal controls; H and CHD = patients with hyperlipidemia and coronary heart disease, respectively. TC = total cholesterol; TG = triglyceride; HDL = high-density lipoprotein; LDL = low-density lipoprotein. Data are shown as median (ranges). The differences in each variable between two groups (N vs. H, H vs. CHD, and N vs. CHD) were determined using the Mann–Whitney U test. The α level was set at <0.05 at a 95% confidence interval.